Latest Post-Marketing Study Data Reinforces ACURATE neo2™ Aortic Valve System Clinical Procedure Success and Safety
MARLBOROUGH, Mass., November 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced top results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of ACURATE neo2MT Aortic valve system. The results, which included a high procedural success rate of 98.4% and low mortality and paravalvular leak (PVL) rates, were presented …